ATE249227T1 - Verwendung von fucosilierten sialilierten n- acetyl-lactosamin-kohlenhydratstrukturen zur hemmung der bakteriellen adhäsion - Google Patents

Verwendung von fucosilierten sialilierten n- acetyl-lactosamin-kohlenhydratstrukturen zur hemmung der bakteriellen adhäsion

Info

Publication number
ATE249227T1
ATE249227T1 AT00921217T AT00921217T ATE249227T1 AT E249227 T1 ATE249227 T1 AT E249227T1 AT 00921217 T AT00921217 T AT 00921217T AT 00921217 T AT00921217 T AT 00921217T AT E249227 T1 ATE249227 T1 AT E249227T1
Authority
AT
Austria
Prior art keywords
lactosamine
sialyl
acetyl
fucosilated
sialilated
Prior art date
Application number
AT00921217T
Other languages
English (en)
Inventor
Thomas Boren
Lennart Hammarstroem
Karl-Anders Karlsson
Susann Teneberg
Original Assignee
Thomas Boren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Boren filed Critical Thomas Boren
Application granted granted Critical
Publication of ATE249227T1 publication Critical patent/ATE249227T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT00921217T 1999-03-19 2000-03-16 Verwendung von fucosilierten sialilierten n- acetyl-lactosamin-kohlenhydratstrukturen zur hemmung der bakteriellen adhäsion ATE249227T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9901007A SE9901007D0 (sv) 1999-03-19 1999-03-19 Use of fucosylated sialylated N-acetyl lactosamin carbohydrate structures for inhibition of bacterial adherence
PCT/SE2000/000514 WO2000056343A1 (en) 1999-03-19 2000-03-16 Use of fucosylated sialylated n-acetyl lactosamine carbohydrate structures for inhibition of bacterial adherence

Publications (1)

Publication Number Publication Date
ATE249227T1 true ATE249227T1 (de) 2003-09-15

Family

ID=20414923

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00921217T ATE249227T1 (de) 1999-03-19 2000-03-16 Verwendung von fucosilierten sialilierten n- acetyl-lactosamin-kohlenhydratstrukturen zur hemmung der bakteriellen adhäsion

Country Status (7)

Country Link
EP (1) EP1169044B1 (de)
JP (1) JP2002539266A (de)
AT (1) ATE249227T1 (de)
AU (1) AU4155700A (de)
DE (1) DE60005164D1 (de)
SE (1) SE9901007D0 (de)
WO (1) WO2000056343A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066502A1 (en) * 2001-02-21 2002-08-29 Boren Thomas Helicobacter pylori sialic acid binding adhesin, saba and saba - gene
ATE429233T1 (de) * 2001-06-29 2009-05-15 Glykos Finland Oy Verwendung mindestens einer glycoinhibitor- substanz gegen infektionskrankheiten
FI20011403A7 (fi) * 2001-06-29 2002-12-30 Carbion Oy Menetelmä ja koostumukset vatsan sairauksien hoitoon
JP2005532793A (ja) * 2002-04-22 2005-11-04 レコファーマ アーベー 微生物付着を阻害するための融合ポリペプチドおよび方法
FI20021989A0 (fi) * 2002-11-06 2002-11-06 Halina Miller-Podraza Korkean affiniteetin Helicobacter pylori-reseptorit ja niiden käyttö
EP2692740A1 (de) * 2012-07-30 2014-02-05 Le Centre National De La Recherche Scientifique Glycanzusammensetzungen, Verfahren zu deren Herstellung und deren Verwendungen als Arzneimittel
WO2024213778A2 (en) 2023-04-12 2024-10-17 Boren Thomas Methods for preventing the development of a gastric disease associated with helicobacter pylori infection without eradicating the infection and for the assessment of the risk of developing such disease
CN116466082B (zh) * 2023-04-23 2025-11-04 江南大学 幽门螺杆菌o2血清型o抗原糖片段在幽门螺杆菌感染检测装置制备中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK76193D0 (da) * 1993-06-25 1993-06-25 Astra Ab Kulhydratderivater
JP3179108B2 (ja) * 1994-03-02 2001-06-25 ネオーズ テクノロジーズ，インコーポレーテッド 胃潰瘍及び十二指腸潰瘍を治療及び阻止する方法

Also Published As

Publication number Publication date
SE9901007D0 (sv) 1999-03-19
AU4155700A (en) 2000-10-09
DE60005164D1 (de) 2003-10-16
EP1169044A1 (de) 2002-01-09
WO2000056343A1 (en) 2000-09-28
JP2002539266A (ja) 2002-11-19
EP1169044B1 (de) 2003-09-10

Similar Documents

Publication Publication Date Title
RÖLLA Why is sucrose so cariogenic? The role of glucosyltransferase and polysaccharides
NO20024011L (no) Karbohydratformulering (prebiotisk hjelpemiddel) for å forbedre immunforsvaret
Seppala et al. Triple therapy of Helicobacter pylori infection in peptic ulcer: a 12-month follow-up study of 93 patients
CA2460749A1 (en) Glycoconjugate vaccines for use in immune-compromised populations
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
EP2272522A3 (de) Therapeutische Zusammensetzungen zur Verwendung bei der Prophylaxe oder Behandlung von Diarrhö
BR0013814A (pt) Métodos de tratamentos de um paciente humano suscetìvel a ou diagnosticado com uma doença com anticorpos anti-erbb2, artigos industrializados, métodos de tratamentos de câncer em pacientes humanos e usos do anticorpo anti-erbb2
MXPA05000880A (es) Probioticos para funciones neuromusculares del intestino.
BR9608041A (pt) Oligossacarídeo sulfatado processo para o tratamento anti-angiogênico anti-metastático e/ou anti-inflamatório de um paciente humano ou outro paciente animal de sangue quente uso de um oligossacarídeo e composição farmacêutica ou veterinária para tratamento anti-angiogênico anti-metastático e/ou anti-inflamatório
BR0206689A (pt) Combinação de probióticos, e, uso desta
BR0112685A (pt) Composição nutricional
BR9714349A (pt) L-nucleosìdeos purina, seus análogos e utilizacões dos mesmos
BRPI0016231B8 (pt) composições compreendendo enzimas úteis para tratar ou melhorar os riscos de infecção do trato digestivo
BRPI0509139A (pt) composição, e, método de estimulação de uma resposta imune em um indivìduo, de tratamento profilático de uma doença, de melhoramento de um sinal ou sintoma associado com uma doença, de alvejamento de um tumor, de inibição do crescimento de tumor, e de detecção de um tumor
EA200701519A1 (ru) Живая аттенуированная ротавирусная вакцина для перорального введения
BRPI0410341A (pt) conjugados de polissacarìdeo-proteìna derivatizados de meningococos multivalente e vacina
IL173481A0 (en) Polysaccharide double-layer microcapsules as carriers for biologically active substance oral administration
SE9600716D0 (sv) Adhesion inhibitors, preparation comprising them and method for producing them
ATE249227T1 (de) Verwendung von fucosilierten sialilierten n- acetyl-lactosamin-kohlenhydratstrukturen zur hemmung der bakteriellen adhäsion
DK1057828T3 (da) Orale trovafloxacin-suspensioner
BRPI0416088A (pt) composição, sistema, e método de tratar condições tais como calcificação vascular
BRPI0410761A (pt) uso de leucina, e, composição para administração entérica a pacientes
MX2008001520A (es) Composiciones de tizanidina y metodos de tratamiento usando las composiciones.
Kumhyr et al. Changes in immunological parameters in patients treated using direct and indirect restorations of the hard tissues of the anterior teeth in combination with an antioxidant

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties